Executive Brief: An Opioid Abuse-Deterrent Roadmap for the Pharmaceutical Industry

The initiative to reduce abuse of prescription drugs has gained significant momentum impacting compliance issues, medical community education, and market opportunities for opioid drug manufacturers.

This paper addresses:

  • Overview of the prescription drug crisis
  • Government Action Directed at the Opioid Drug Abuse Epidemic
  • Medical Community Response—Where Do Doctors Stand?
  • FDA Position on Abuse-Deterrent Opioid Drug Products
  • Three Benefits of Abuse-Deterrent Determination for Opioid Manufacturers
  • Factors Contributing to Opioid Abuse-Deterrence
  • Abuse-Deterrence Determination
  • In Vitro Manipulation and Extraction Studies Approaches

Download White Paper (PDF) Here


Ready to Get Started?

Connect with an Expert


Topics: Abuse-Deterrence White Paper / eBook